Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in...
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) currently trades at a P/E ratio of 26.83 (historical range: 25.59–27.46, median: 26.55), placing it at the 79th percentile — above its historical average, P/S ratio of 4.06 (range: 3.87–4.15, 79th percentile — above its historical average), EV/EBITDA of 21.56 (range: 20.71–22.00, 79th percentile).
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 26.83 | 25.59 | 26.55 | 27.46 | 79th | above its historical average |
| P/S Ratio | 4.06 | 3.87 | 4.01 | 4.15 | 79th | above its historical average |
| EV/EBITDA | 21.56 | 20.71 | 21.37 | 22.00 | 79th | above its historical average |